Belzutifan

Introduction Overview

Generic Name

belzutifan

Brand Name

Welireg

Dosage Form

tablet (40 mg)

Drug Class

Miscellaneous antineoplastics

Pharmacokinetics

Absorption:
Belzutifan (Welireg) is administered orally, with its tablet formulation designed for once-daily dosing. The absorption of belzutifan occurs in the gastrointestinal tract, with or without food, indicating a flexible administration schedule. Pharmacokinetic data suggests that belzutifan exhibits adequate oral bioavailability, enabling sufficient systemic drug levels to inhibit its molecular target. Food intake does not significantly affect the extent of absorption, allowing for administration without regard to meals, which improves patient compliance.

Distribution:
Clinical studies demonstrate that belzutifan is widely distributed throughout the body after absorption. Though detailed tissue distribution data are limited, the drug’s ability to reach tumorous tissues, including central nervous system hemangioblastomas, pancreatic neuroendocrine tumors, and renal cell carcinomas, highlights its capability to penetrate diverse tissue compartments. The distribution volume indicates moderate to extensive tissue binding. Protein binding status, which influences distribution, is moderately high, predominantly to plasma proteins, potentially affecting free drug concentrations and pharmacodynamics.

Metabolism:
Belzutifan undergoes hepatic metabolism primarily via cytochrome P450 enzymes; established evidence indicates involvement of CYP isoforms, possibly including CYP3A4, which are responsible for oxidation and biotransformation. Oxidative metabolism converts belzutifan into various metabolites, some of which may be pharmacologically inactive. The metabolic pathway is critical in modulating drug clearance and potential drug-drug interactions, especially with co-administered agents influencing CYP enzyme activity. Phase II conjugation reactions may also contribute to metabolism, although phase I oxidation is predominant.

Elimination:
The elimination of belzutifan occurs via renal and fecal excretion of parent drug and metabolites. The drug exhibits a half-life suitable for once-daily dosing, which supports steady plasma concentration maintenance. Renal clearance contributes significantly to overall elimination, necessitating monitoring in patients with renal impairment. Hepatobiliary excretion also plays a role. Clinical pharmacokinetic studies confirm stable elimination kinetics, with dose adjustments recommended in cases of altered hepatic or renal function. Therapeutic drug monitoring is not standard but may be warranted under specific clinical circumstances.

Dosage Forms

Available Dosage Forms:
Welireg is available exclusively as an oral film-coated tablet containing 40 mg of the active ingredient belzutifan. The tablet is formulated to be swallowed whole without crushing, chewing, or breaking.

Dosages for Adults and Adolescents:
- Adults typically initiate treatment at 120 mg orally once daily, equating to three 40 mg tablets once daily. This regimen continues until disease progression or the emergence of unacceptable toxicity.
- Pediatric dosing is weight-based:
- Patients weighing 40 kg or more receive 120 mg orally once daily.
- Patients weighing less than 40 kg receive 80 mg orally once daily, corresponding to two 40 mg tablets.
The dosing schedule emphasizes adherence to a fixed once-daily administration time, with or without food to optimize drug exposure and patient compliance.

Specific Patient Populations:
- Renal and Hepatic Impairment: While specific dose adjustments are not conclusively defined, patients with significant renal or hepatic dysfunction require careful monitoring for toxicity due to altered drug clearance.
- Pregnancy and Fertility Considerations: Use is contraindicated during pregnancy due to potential fetal harm; effective contraception using non-hormonal methods is required during therapy and for at least one week following the last dose.
- Pediatric Use: Approved for patients 12 years and older with pheochromocytoma or paraganglioma.

The available dosage form facilitates precise dose titration and flexibility for weight-based pediatric dosing, enabling tailored therapy according to clinical needs.

Mechanism Of Action

Belzutifan, the active component of Welireg, functions as a selective inhibitor of hypoxia-inducible factor 2 alpha (HIF-2α), a transcription factor implicated in tumor growth and angiogenesis particularly under hypoxic conditions that are common in solid tumors. Under normoxic conditions, HIF-α subunits are rapidly degraded; however, hypoxia stabilizes HIF-2α, leading to the transcription of genes promoting angiogenesis, cell proliferation, and survival. By binding to HIF-2α, belzutifan disrupts its heterodimerization with HIF-1β, thereby preventing its binding to DNA hypoxia response elements and transcriptional activity.

On the molecular level, this blockade suppresses expression of downstream target genes such as vascular endothelial growth factor (VEGF), erythropoietin, and glucose transporter-1, which play crucial roles in tumor vascularization, oxygen delivery, and metabolic adaptation. This molecular interference hampers the tumor's ability to sustain its hypoxic microenvironment and growth potential.

Belzutifan's action differs fundamentally from conventional chemotherapeutic agents, as it selectively targets a transcriptional regulator rather than inducing cytotoxicity directly. This specificity offers a therapeutic advantage by potentially reducing off-target effects and improving tolerability profiles.

Clinical trials demonstrate that this mechanism effectively reduces tumor size in von Hippel-Lindau disease-associated CNS hemangioblastomas, pancreatic neuroendocrine tumors, and renal cell carcinoma. The targeted inhibition of HIF-2α also shows promise in treating advanced RCC post prior therapies (immune checkpoint inhibitors and VEGF tyrosine kinase inhibitors), highlighting its role in overcoming therapeutic resistance pathways and addressing hypoxia-driven tumor progression.

Pharmacological Actions

Selective inhibition of hypoxia-inducible factor 2 alpha (HIF-2α) transcriptional activity
Suppression of gene expression involved in angiogenesis such as VEGF
Reduction of erythropoietin production impacting red blood cell regulation
Inhibition of tumor adaptation to hypoxic microenvironment leading to decreased tumor growth
Modulation of tumor metabolism through interference with glucose transporter expression
Antineoplastic activity demonstrated in von Hippel-Lindau disease associated tumors and renal cell carcinoma
Non-cytotoxic targeted agent distinct from traditional chemotherapies
Potential enhancement of efficacy when used sequentially after immune checkpoint inhibitors and VEGF-TKI therapies
Oral once-daily administration optimizing patient compliance
Activity in pediatric patients 12 years and older with PPGL
Minimal off-target pharmacological effects due to selective molecular target
Interference with hypoxia-driven gene transcription critical in tumor survival
Downregulation of pathways implicated in tumor angiogenesis and proliferation
Influence on tumor microenvironment remodeling via HIF pathway inhibition
Potential to delay need for surgical intervention in certain VHL-related tumor types

Therapeutic Or Clinical Uses

Treatment of adults with von Hippel-Lindau (VHL) disease who do not require immediate surgery for CNS hemangioblastomas, pancreatic neuroendocrine tumors, or renal cell carcinoma
Management of advanced renal cell carcinoma (RCC) following progression on programmed death receptor-1 (PD-1) or programmed death-ligand 1 (PD-L1) inhibitors and VEGF tyrosine kinase inhibitors
Therapy for locally advanced, unresectable, or metastatic pheochromocytoma or paraganglioma (PPGL) in adult and pediatric patients aged 12 years and older
Reduction in tumor burden for central nervous system vascular tumors associated with VHL syndrome
Alternative systemic treatment option in patients with RCC resistant or intolerant to previous immunotherapy and targeted therapies
Adjunct therapy aiming to delay surgical intervention in VHL-associated tumors
Potential improvement in quality of life by controlling tumor growth and reducing complications
Off-label investigational use in other HIF-2α-driven malignancies under clinical trial settings
Treatment modality with unique mechanism differing from traditional chemotherapy and immunotherapy agents
First-in-class agent approved specifically for VHL disease manifestations
Use in pediatric oncology for PPGL management beyond standard therapies
Targeted approach to address tumor hypoxia pathways implicated in cancer progression
Treatment option with oral formulation facilitating long-term outpatient management
Option for patients with contraindications to immunotherapy or VEGF inhibitors
Disease-modifying therapy reducing tumor progression rather than solely symptomatic relief

Side Or Adverse Effects

Anemia characterized by decreased hemoglobin levels, potentially severe requiring transfusion
Headache occurring commonly in patients treated for VHL disease
Dizziness and general tiredness reported in both adult and pediatric patients
Nausea, potentially impacting tolerability and compliance
Hyperglycemia manifestations including increased thirst, urination, and fruity breath
Abnormal kidney function test results indicating possible renal impairment
Muscle and joint pain particularly noted in advanced RCC patient population
Laboratory abnormalities such as increased creatinine, elevated liver enzymes (alanine and aspartate aminotransferases), decreased lymphocytes, hyponatremia, and hyperkalemia
Serious allergic reactions including hives, facial or throat swelling, difficulty breathing necessitating immediate medical intervention
Risk of pneumonia and pleural effusion reflecting pulmonary complications
Potential for sepsis demanding vigilant infection monitoring
Vision problems possibly related to drug effects on vascular or neural tissues
Fatigue and general malaise impacting daily activity
Risk of hemorrhage requiring close clinical surveillance
Delayed or permanent discontinuation of therapy may be necessary in severe adverse events

Precautions

Monitor hemoglobin and red blood cell counts before and during therapy to detect anemia early
Regular assessment of renal and hepatic function tests due to potential organ impairment
Screen for symptoms of hypoxia including shortness of breath, chest pain, and elevated heart rate
Evaluate blood glucose levels periodically to manage potential hyperglycemia
Use non-hormonal contraception in male and female patients during therapy and for at least one week post-treatment
Pregnancy testing recommended prior to initiation in females of reproductive potential
Avoid breastfeeding during treatment and for one week after last dose due to unknown drug excretion in milk
Inform healthcare providers about all concomitant medications to assess for interactions, especially hormonal contraceptives and CYP enzyme modulators
Be alert for signs of infection and bleeding, given risks of pneumonia, sepsis, and hemorrhage
Provide patient education on recognizing serious side effects requiring urgent care
Adjust or discontinue therapy based on toxicity tolerability per clinical guidelines
Advise patients not to alter dose or stop medication without medical consultation
Counsel regarding potential fertility impairment in both males and females
Monitor pediatric patients closely given weight-based dosing and developmental considerations
Caution in patients with pre-existing anemia or cardiovascular comorbidities

Warnings

Anemia and low oxygen levels are common and may necessitate blood transfusions, oxygen therapy, or hospitalization
Potential teratogenic effects and fetal harm if used during pregnancy; strict pregnancy prevention measures required
Concomitant use with hormonal contraceptives may reduce contraceptive efficacy, leading to unintended pregnancy
Delayed hypersensitivity reactions and severe allergic responses can occur
Usage necessitates frequent monitoring to detect early signs of serious adverse events
Therapy may be interrupted or discontinued if severe toxicities develop
Risk of pulmonary adverse events including pneumonia and pleural effusion
Potential for hemorrhagic events warranting close monitoring of bleeding risk
Risk of sepsis requiring prompt identification and treatment of infections
Hepatic enzyme elevations may indicate liver injury; monitor transaminases regularly
Do not use during breastfeeding due to potential exposure to infant
May cause vision disturbances, requiring ophthalmologic assessment if symptomatic
Safety and efficacy in patients under 12 years of age have not been established
Patients should be counseled on signs of hypoxia and instructed to seek immediate medical attention if these occur
Concomitant medications that induce or inhibit CYP enzymes may alter drug levels and toxicity

Contraindication

Known hypersensitivity to belzutifan or any tablet excipients
Pregnancy due to risk of fetal harm
Breastfeeding during treatment and for 1 week following last dose
Concomitant use with hormonal contraceptives without additional non-hormonal contraception due to reduced contraceptive efficacy
Severe anemia or untreated anemia requiring immediate correction prior to initiating therapy
Patients with prior severe allergic reactions to similar hypoxia-inducible factor inhibitors
Known bleeding disorders that are uncontrolled may contraindicate use without careful risk-benefit assessment
Patients unable to comply with mandatory monitoring requirements
Concurrent participation in other experimental cancer drug trials without medical supervision
Known active infections or sepsis until adequately treated and stabilized
Pediatric patients under 12 years of age because safety and effectiveness have not been established
Severe hepatic impairment due to lack of dosage data and increased toxicity risk
Severe renal impairment without adequate monitoring due to altered elimination
Concurrent use of strong CYP3A4 inducers or inhibitors without careful management
Use in patients with uncontrolled cardiovascular diseases requiring caution and specialist consultation

Drug Interactions

Concurrent use with hormonal contraceptives may lead to contraceptive failure and breakthrough bleeding
Potential drug interactions with CYP3A4 inhibitors which could increase belzutifan plasma levels and toxicity
CYP3A4 inducers may lower plasma concentrations of belzutifan, reducing efficacy
Co-administration with other anticancer agents requires monitoring for additive toxicities
Use with drugs affecting hematologic parameters can exacerbate anemia or other blood dyscrasias
Interaction with agents causing QT prolongation not well studied; caution advised
Possible interaction with medications influencing glucose metabolism, requiring glucose monitoring
Caution when combining with nephrotoxic or hepatotoxic drugs due to overlapping organ toxicities
Potential pharmacodynamic interactions with immunotherapies and VEGF pathway inhibitors used prior to belzutifan
Avoid concomitant use with strong inhibitors or inducers of drug transporters involved in belzutifan distribution
Interactions with over-the-counter supplements such as St. John’s Wort that induce CYP enzymes may reduce drug efficacy
Monitoring for increased bleeding risk when combined with anticoagulants or antiplatelet agents
Possible alterations in metabolism when co-administered with herbal products; clinical significance unknown
Patients should inform healthcare providers of all drugs, supplements, and herbal products to avoid interactions
Therapeutic drug monitoring or dose adjustments may be necessary when significant interactions are suspected

Preparations Of The Drug

Welireg film-coated tablets containing 40 mg of belzutifan
Tablets formulated with inactive ingredients including croscarmellose sodium, hypromellose acetate succinate, magnesium stearate, mannitol, microcrystalline cellulose, and silicon dioxide
Film-coating components include FD&C Blue #2 aluminum lake, polyethylene glycol, polyvinyl alcohol, talc, and titanium dioxide to ensure tablet integrity and stability
Packaged in bottles equipped with two desiccant canisters to maintain dryness and drug stability
Storage recommended at controlled room temperature between 20°C to 25°C (68°F to 77°F)
Supplied exclusively as oral tablets for once-daily dosing regimen
Manufactured by Merck Sharp & Dohme Corp, ensuring quality control and regulatory compliance
Manufacturing includes stringent standards for purity, potency, and batch-to-batch consistency
Each tablet is designed for swallowing whole; not intended to be crushed, chewed, or split to maintain pharmacokinetic profile
Available in prescription form only due to specialized indications and required medical supervision
Contains non-hormonal excipients ensuring minimal risk of hormonal interference
Each packaging unit includes patient information leaflets outlining dosing, administration, and safety information
The formulation supports long-term storage stability with clear labeling and usage instructions
Disposal after expiration requires adherence to pharmaceutical waste regulations
Modifications for pediatric dosing achieved by adjusting tablet count rather than tablet strength variations